Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices

Oncologist

Volumn 15, Issue 6, 2010, Pages 566-576

  Wong, Yu Ning ^a,b   Hamilton, Olivia ^a   Egleston, Brian ^a   Salador, Kevin ^c   Murphy, Camara ^a   Meropol, Neal J ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; DEMOGRAPHY; FEMALE; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; SOFT TISSUE CANCER; TESTIS CANCER; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; FINANCIAL MANAGEMENT; MIDDLE AGED; NEOPLASMS; PATIENT SATISFACTION; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; FEMALE; FINANCING, PERSONAL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 77954963593     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0307     Document Type: Article

References (19)

1. Goldman DP, Joyce GF, Escarce JJ et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-2350.
2. Hsu J, Price M, Huang J et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006;354:2349-2359.
3. National Survey of Households Affected by Cancer. Menlo Park, CA: The USA Today/Kaiser Family Foundation/Harvard School of Public Health, 2006:1-50.
4. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
5. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
6. Ramsey SD. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol 2007;25:175-179.
7. Goldman DP, Joyce GF, Lawless G et al. Benefit design and specialty drug use. Health Aff (Millwood) 2006;25:1319-1331.
8. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007;25:180-186.
9. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 2009;27:3868-3874.
10. Carroll J. When new drugs are costly, how high to raise copays? Manag Care 2006;15:20-21, 25-26, 29-30.
11. Kaa K. Medicare challenges and solutions-reimbursement issues in treating the patient with colorectal cancer. J Manag Care Pharm 2007;13(6 suppl C):S19-S26.
12. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
13. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070.
14. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
15. Day JC, Newburger EC. The big payoff: Educational attainment and synthetic estimates of work-life earnings. Curr Popul Rep 23 Spec Stud 2002;23-210.
16. Aristides M, Chen J, Schulz M et al. Conjoint analysis of a new chemotherapy: Willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. Pharmacoeconomics 2002;20:775-784.
17. Leighl NB, Tsao WS, Zawisza DL et al. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006;51:115-121.
18. Weinfurt KP. Value of high-cost cancer care:Abehavioral science perspective. J Clin Oncol 2007;25:223-227.
19. Meropol NJ, Egleston BL, Buzaglo JS et al. Cancer patient preferences for quality and length of life. Cancer 2008;113:3459-3466.